Navigation Links
Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
Date:10/12/2011

CRANBURY, N.J., Oct. 12, 2011 /PRNewswire/ -- Oncobiologics, Inc. announced today that is has named Scott Canute, a former President at both Eli Lilly and Genzyme, to its Board of Directors.  

Over the course of his 30-year career, Mr. Canute played a vital role in leading Eli Lilly's global manufacturing operations.  Most recently, he spent more than a year as President of Global Manufacturing and Corporate Operations for Genzyme, where he led a major turnaround effort.

"Scott Canute has been a distinguished leader at major biopharmaceutical organizations throughout his career," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D.  "I have known and admired Scott as my mentor for many years, and I am honored that he will share his experience and strategic insight to our efforts at Oncobiologics.  We look forward to guidance from Scott as a member of our board."

"Oncobiologics has assembled an impressive team of industry leaders, and already has developed a promising pipeline," said Mr. Canute.  "Although the company is a start-up, it has the horsepower of a much more established organization.  I look forward to helping Pankaj steer the company through this exciting stage."

Mr. Canute earned a Master of Business Administration from the Harvard Business School.  He also earned a B.S. in Chemical Engineering at the University of Michigan, where he graduated with Highest Honors.

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Omeros Appoints David A. Mann to its Board of Directors
4. RainDance Technologies Appoints Olex Vice President, System Development
5. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
6. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
7. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
8. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
9. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
10. UltraShape Appoints Assaf Eyal as President & CEO
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):